MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma - MEDI2228

Exclusion Criteria

• Any of the following would exclude the subject from participation in the study:
• Target Disease:
• 1. Subjects who have previously received an autologous stem cell transplant if less than 90 days have elapsed from the time of transplant or the subject has not recovered from transplant associated toxicities prior to the first scheduled dose of MEDI2228
• 2. Subjects who have previously received an allogeneic stem cell transplant
• 3. Central nervous system (CNS) involvement(including meningeal involvement) by MRI or cerebrospinal fluid exam
• 4. Known history of polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome, plasma cell leukemia, Waldenstrom’s macroglobulinemia, or amyloidosis
• Medical History and Concurrent Diseases:
• 5. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results